Stevanato secures €200 million financing for global expansion

Published 23/07/2025, 11:40
Stevanato secures €200 million financing for global expansion

PIOMBINO DESE, Italy - Stevanato Group S.p.A. (NYSE:STVN), a $6.7 billion market cap pharmaceutical solutions provider with annual revenues exceeding $1.2 billion, has secured €200 million in financing through agreements with three Italian banks to support its manufacturing expansion in Italy and the United States, according to a company press release.

The drug containment and delivery solutions provider has obtained €100 million from BNL BNP Paribas, €50 million from Cassa Depositi e Prestiti (CDP), and €50 million from Banco BPM to fund capital expenditure projects at its facilities in Cisterna di Latina, Italy, and Fishers, Indiana. According to InvestingPro data, the company maintains a moderate debt level with a healthy debt-to-equity ratio of 0.28.

The funds will primarily support the expansion of pre-filled syringe production capacity at both locations, with CDP’s contribution specifically earmarked for enhancing production at the Italian plant and setting up future capacity for ready-to-use cartridges.

"These agreements are an important element to Stevanato Group’s financial strategy, allowing us to capitalize on robust customer demand," said Marco Dal Lago, Chief Financial Officer of Stevanato Group. InvestingPro analysis shows the company is currently trading above its Fair Value, with 6 analysts recently revising their earnings expectations upward for the upcoming period. Additional insights and detailed valuation metrics are available in InvestingPro’s comprehensive research report.

The financing will help Stevanato scale commercial production to meet growing demand for biologics programs from pharmaceutical customers. The company plans to complete ongoing construction for device manufacturing at its Fishers facility while expanding production capabilities in Italy.

Stevanato Group, founded in 1949, provides drug containment, delivery, and diagnostic solutions to pharmaceutical, biotechnology, and life sciences industries. The company has been expanding its global footprint to strengthen its position in key markets, particularly in North America. Financial indicators from InvestingPro demonstrate the company’s solid performance, with a 3.8% revenue growth and strong liquidity position reflected in a current ratio of 1.83.

The three Italian banks expressed support for Stevanato’s growth strategy, citing the company’s focus on innovation and its role in the strategic pharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.